McDermott Will & Emery advised Maat Pharma, a late-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) aimed at improving the survival of cancer patients through modulation of the immune system, in a EUR13 million capital increase from its historical shareholders, Biocodex, PSIM fund represented by Bpifrance Investissement and an existing American-European investor.
The funds raised will help support the company in advancing its next development milestones, including the submission of the marketing authorization application for MaaT013 in aGvH in Europe, the expansion strategy in the United States, and the conclusion of potential partnerships for its hemato-oncology products in Europe.

The McDermott team involved in this operation was composed of:

Corporate & stock market aspects

• Bertrand Delafaye, Partner
• Sophie Lafay, Counsel
• Lucie Martin, Counsel
• Henri Nalbandyan, Associate

Life Sciences aspects

• Emmanuelle Trombe, Partner
• Amel El Mouttaki, Associate

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Frankfurt, April 2, 2025 –– McDermott Will & Emery has advised the shareholders of the Alfatec Group on the sale of the majority of the shares in the company to the investment company AUCTUS and on the reinvestment of the shareholders. AUCTUS invests in Alfatec through the AUCTUS V fund.

Founded in 1978, Alfatec GmbH & Co. KG headquartered in Rednitzhembach, Germany, is a product specialist in the field of electronic components.

AUCTUS Capital Partners AG is one of the most active European mid-market investment companies with nearly 450 investments since its founding in 2001. AUCTUS primarily invests in majority stakes in companies with annual revenues between €10 million and €150 million.

The McDermott team was led by partners Michael Cziesla and Christian Marzlin and comprised partners Maximilian Clostermeyer, Heiko Kermer, Christian Rolf and Alexander Klein; counsel Marcus Fischer and Laura Stammwitz as well as associates Daniel Lenz, Lea Hauser, Hannah Henseling, Jan Ischreyt and Sönke Wassermann.

Munich, April 1, 2025 – McDermott Will & Emery has advised Main Capital Partners on its majority investment in VOQUZ Labs AG, a German provider of SAP license management and IT spend optimization software. The transaction, in which Main Capital Partners is acquiring a 95.3% stake, is expected to close by the end of April 2025. Upon closing, Main intends to initiate a squeeze-out of minority shareholders.

The acquisition marks the seventh platform investment for Main Capital Partners’ latest fund, Main Foundation II, launched in April 2024.

VOQUZ Labs, listed on the open market of the Munich Stock Exchange and Vienna Stock Exchange, is headquartered in Berlin and employs approximately 40 staff. The company offers a highly specialized software portfolio including samQ, visoryQ, and remQ. These solutions enable enterprises to automate SAP license management, streamline access governance, and ensure compliance.

Main Capital Partners is a leading software investor in the DACH region, the Benelux countries, the Nordic countries and the United States, with approximately €6 billion in assets under management and an active portfolio of more than 50 software groups.

McDermott regularly advises Main Capital on transactions, including financings.

The McDermott team was led by partners Felix Ganzer (PE / Public M&A) and Holger Ebersberger (PE / Public M&A), and included Marcus Fischer (Tax), Alexandra Prato (PE), Parsin Walsi (PE), Marion Dalvai-König (PE), Philipp Grenzebach (Corporate), Jan Ischreyt (Corporate), Annabelle Rau (Corporate), Claus Färber (IP), Thomas Gennert (Employment), Janek Joosten (Employment), Dustin Schwerdtfeger (Finance), Matthias Bosbach (Finance) and Romy Lanz (Finance).